Tumor assessment criteria in phase I trials: Beyond RECIST

Journal of Clinical Oncology

Volumn 31, Issue 3, 2013, Pages 395-

  Levy, Antonin ^a   Hollebecque, Antoine ^a   Ferté, Charles ^a   Koscielny, Serge ^a   Fernandez, Mariana ^a   Soria, Jean Charles ^a   Massard, Christophe ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; SORAFENIB;

CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY CARCINOMA; LETTER; LIVER CELL CARCINOMA; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR BURDEN;

EID: 84873364068     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.2184     Document Type: Letter

References (9)

1. Jain RK, Lee JJ, Ng C, et al: Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol 30:2684-2690, 2012
2. El-Maraghi RH, Eisenhauer EA: Review of phase II trial designs used in studies of molecular targeted agents: Outcomes and predictors of success in phase III. J Clin Oncol 26:1346-1354, 2008
3. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
4. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
5. Wahl RL, Jacene H, Kasamon Y, et al: From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S-150S, 2009 (suppl 1)
6. Wolchok JD, Hoos A, O'Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15:7412-7420, 2009
7. Gomez-Roca C, Koscielny S, Ribrag V, et al: Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer 47:2512-2516, 2011
8. Ferte C, Albiges L, Soria J-C, et al: The use of tumor growth rate (TGR) in evaluating sorafenib and everolimus treatment in mRCC patients: An integrated analysis of the TARGET and RECORD phase III trials data. J Clin Oncol 30:287s, 2012 (suppl 15; abstr 4540)
9. Ang JE, Olmos D, Moreno Garcia V, et al: Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit. J Clin Oncol 29:178s, 2011 (suppl 15; abstr 2555)